Edgestream Partners L.P. Acquires Shares of 4,742 Edwards Lifesciences Co. (NYSE:EW)

Edgestream Partners L.P. bought a new position in shares of Edwards Lifesciences Co. (NYSE:EW) in the second quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor bought 4,742 shares of the medical research company’s stock, valued at approximately $438,000.

Several other large investors also recently modified their holdings of the business. DSM Capital Partners LLC bought a new position in Edwards Lifesciences during the 4th quarter valued at approximately $28,000. Crewe Advisors LLC purchased a new stake in Edwards Lifesciences in the first quarter worth $28,000. First Community Trust NA bought a new stake in Edwards Lifesciences in the second quarter valued at $29,000. Riverview Trust Co purchased a new position in Edwards Lifesciences during the 1st quarter valued at $34,000. Finally, Pingora Partners LLC bought a new stake in shares of Edwards Lifesciences during the 4th quarter valued at about $38,000. 79.46% of the stock is owned by institutional investors.

Insider Activity

In other news, VP Daveen Chopra sold 1,250 shares of the firm’s stock in a transaction dated Tuesday, August 20th. The shares were sold at an average price of $69.95, for a total transaction of $87,437.50. Following the sale, the vice president now owns 29,333 shares of the company’s stock, valued at approximately $2,051,843.35. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. In related news, VP Daveen Chopra sold 1,250 shares of the firm’s stock in a transaction that occurred on Tuesday, August 20th. The shares were sold at an average price of $69.95, for a total value of $87,437.50. Following the transaction, the vice president now owns 29,333 shares of the company’s stock, valued at $2,051,843.35. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, VP Donald E. Bobo, Jr. sold 5,000 shares of the company’s stock in a transaction that occurred on Wednesday, August 14th. The shares were sold at an average price of $66.08, for a total transaction of $330,400.00. Following the sale, the vice president now directly owns 46,936 shares of the company’s stock, valued at $3,101,530.88. The disclosure for this sale can be found here. Insiders have sold a total of 16,250 shares of company stock valued at $1,218,138 in the last 90 days. 1.29% of the stock is currently owned by insiders.

Edwards Lifesciences Price Performance

Shares of NYSE:EW opened at $66.83 on Monday. The business has a 50-day simple moving average of $69.89 and a two-hundred day simple moving average of $82.80. The company has a debt-to-equity ratio of 0.08, a quick ratio of 2.87 and a current ratio of 3.71. The firm has a market cap of $40.27 billion, a price-to-earnings ratio of 28.81, a price-to-earnings-growth ratio of 2.85 and a beta of 1.13. Edwards Lifesciences Co. has a fifty-two week low of $58.93 and a fifty-two week high of $96.12.

Edwards Lifesciences (NYSE:EW) last announced its quarterly earnings results on Wednesday, July 24th. The medical research company reported $0.70 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.69 by $0.01. The firm had revenue of $1.63 billion for the quarter, compared to the consensus estimate of $1.65 billion. Edwards Lifesciences had a net margin of 24.55% and a return on equity of 22.35%. The business’s quarterly revenue was up 6.7% compared to the same quarter last year. During the same quarter last year, the firm posted $0.66 EPS. On average, analysts expect that Edwards Lifesciences Co. will post 2.7 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several analysts have commented on the stock. Daiwa America upgraded shares of Edwards Lifesciences to a “strong-buy” rating in a report on Wednesday, July 31st. Deutsche Bank Aktiengesellschaft dropped their price target on Edwards Lifesciences from $103.00 to $85.00 and set a “buy” rating on the stock in a research report on Thursday, July 25th. Jefferies Financial Group downgraded Edwards Lifesciences from a “buy” rating to a “hold” rating and decreased their price objective for the stock from $85.00 to $70.00 in a report on Wednesday, September 18th. Piper Sandler dropped their target price on shares of Edwards Lifesciences from $88.00 to $73.00 and set a “neutral” rating on the stock in a report on Thursday, July 25th. Finally, Baird R W lowered shares of Edwards Lifesciences from a “strong-buy” rating to a “hold” rating in a research note on Thursday, July 25th. Sixteen research analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, Edwards Lifesciences has a consensus rating of “Hold” and an average price target of $79.82.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.